Men, there’s no shame of needing a little boost. According to Hims & Hers, 20% of men experience erectile dysfunction (ED) in their 20s, while 30% do in their 30s. Hims & Hers (NASDAQ:HIMS) built a $1.6B business in providing treatments for stigmatized conditions like ED, along with hair loss, skincare and mental illnesses. Hims…
Read more
Teladoc is falling after earnings — but here’s why it deserves a second look
Teladoc Health (NYSE:TDOC), the virtual healthcare platform, reported its second-quarter earnings report with sales growing 109% to $503m, and virtual patient visits up 28% to 3.5m. But there’s a metric turning investors off: Losses grew to $133m — sending its stock down 10% before recovering the majority of its losses through the day. What’s the…
Read more